India approves its first Dengue Vaccine - QDENGA

DCGI gave market authorization on July 20, 2026.

Key Details about QDENGA

1. Who makes it

Takeda Biopharmaceuticals - Japanese pharma company

Partnering with Indian vaccine maker Biological E for manufacturing up to 50 million doses annually. 

2. Who can take it

Age: 4 to 60 years

Biggest advantage: Can be given irrespective of prior dengue infection

No pre-vaccination screening/testing needed. 

3. How it works

Type: Live-attenuated tetravalent vaccine

Covers: All 4 dengue virus serotypes - DENV-1, DENV-2, DENV-3, DENV-4

Doses: 2 doses, 0.5ml subcutaneous injection, 3 months apart . 

4. Efficacy Data

80.2% efficacy against confirmed dengue cases 1 year after 2nd dose

90.4% efficacy against dengue-related hospitalizations after 18 months

7-year data shows continued protection against infection + hospitalization . 

5. When will it be available

Launch: Expected in first half of 2027

Initial rollout: Through private healthcare settings first

Already approved in 43 countries with 32+ million doses distributed globally since 2022 . 

Why this is a big deal

India's burden: 232,425 cases + 233 deaths reported in 2024. Cases up 11-fold in last 2 decades

First vaccine-based strategy: Until now we only had mosquito control + supportive care

No screening needed: Unlike earlier dengue vaccines, you don't need to test if you had dengue before   . 

Important notes

Not a "silver bullet": Mosquito control, surveillance + awareness still essential

Post-marketing studies mandated within 6 months of rollout

Indian trial data: Phase III DEN-302 trial conducted in India with ages 4-60 .